vida: extract claims from 2026-04-23-science-hedonic-eating-dopamine-glp1

- Source: inbox/queue/2026-04-23-science-hedonic-eating-dopamine-glp1.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Hedonic eating has a specific dopamine circuit substrate that is pharmacologically addressable but the circuit is continuously activated by environmental triggers making behavioral and biological factors inseparable
+confidence: experimental
+source: Zhu et al., Science 2025, Vol. 387, eadt0773
+created: 2026-04-23
+title: The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
+agent: vida
+sourced_from: health/2026-04-23-science-hedonic-eating-dopamine-glp1.md
+scope: causal
+sourcer: Zhenggang Zhu, Scott M. Sternson et al., Janelia Research Campus
+supports: ["Big-Food-companies-engineer-addictive-products-by-hacking-evolutionary-reward-pathways-creating-a-noncommunicable-disease-epidemic-more-deadly-than-the-famines-specialization-eliminated"]
+related: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm", "Big-Food-companies-engineer-addictive-products-by-hacking-evolutionary-reward-pathways-creating-a-noncommunicable-disease-epidemic-more-deadly-than-the-famines-specialization-eliminated"]
+---
+
+# The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
+
+The study identifies the precise neural circuit mediating hedonic eating: periLC_VGLUT2 → VTA_VGAT ⊣ VTA_DA → NAc dopamine. This circuit encodes palatability and drives consumption beyond homeostatic need. GLP-1 receptor agonists work by pharmacologically suppressing this circuit's responsiveness. This finding dissolves the behavioral-biological dichotomy for obesity: what appears as a 'behavioral' pattern (eating highly palatable food despite satiety) is the direct output of a specific dopamine reward circuit. However, the circuit is continuously activated by environmental triggers—engineered food palatability. The implication is that behavioral factors (food environment, food engineering) remain primary DRIVERS even though the mechanism is biological, because they continuously activate the biological system. Pharmacological intervention addresses the circuit but must be continuous because the triggering environment is continuous. This reframes the 'behavioral vs. clinical' debate: they are not competing explanations but different levels of a single causal chain where environmental factors activate biological circuits that produce behavioral patterns.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -17,3 +17,10 @@ related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metaboli
 # GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
 
 A systematic review of ClinicalTrials.gov identified 33 registered trials examining GLP-1 receptor agonists for substance use disorders: 15 for alcohol use disorder, 9 for nicotine/tobacco, 4 for cocaine, 4 for opioid use disorder, and 1 for methamphetamine. The mechanistic basis is shared with obesity treatment: GLP-1 receptors are expressed in the mesolimbic dopamine system (VTA, nucleus accumbens, amygdala) that underlies both hedonic eating and substance addiction. Early clinical evidence supports this mechanism: an RCT showed low-dose semaglutide reduced laboratory alcohol self-administration, drinks per drinking day, and craving in people with AUD. Real-world analysis by Qeadan et al. found that among people with pre-existing SUD, GLP-1 users showed fewer ER visits, hospitalizations, and deaths related to substance use. Animal studies demonstrate GLP-1s lower self-administration of opioids (heroin, fentanyl, oxycodone) and reduce relapse-like behavior. The breadth of the trial pipeline—with semaglutide as the most studied agent (n=15 trials)—indicates this is being taken seriously as a paradigm shift for addiction medicine. However, most OUD data remains in animal models, and human trial results are not yet published. The field is 2-3 years from definitive clinical evidence, making this experimental rather than proven.
+
+
+## Extending Evidence
+
+**Source:** Zhu et al., Science 2025, Vol. 387, eadt0773
+
+The same VTA dopamine circuit identified for hedonic eating (periLC → VTA_DA → NAc) is the mesolimbic dopamine pathway implicated in addiction. The study shows GLP-1Rs suppress VTADA neuron responsiveness during consumption, providing the specific circuit mechanism for GLP-1's effects on substance use disorders. The tolerance finding (circuit adaptation during repeated treatment) may also explain variable efficacy in addiction trials.

domains/health/hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: GLP-1 receptor agonists suppress VTADA neuron activity during food consumption reducing hedonic eating but mice recover palatable food appetite during repeated treatment through circuit adaptation
+confidence: experimental
+source: Zhu et al., Science 2025, Vol. 387, eadt0773
+created: 2026-04-23
+title: Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
+agent: vida
+sourced_from: health/2026-04-23-science-hedonic-eating-dopamine-glp1.md
+scope: causal
+sourcer: Zhenggang Zhu, Scott M. Sternson et al., Janelia Research Campus
+related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
+---
+
+# Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
+
+Researchers at Janelia Research Campus identified the specific neural circuit controlling hedonic eating: peri-locus ceruleus → ventral tegmental area dopamine neurons → nucleus accumbens. VTADA neurons encode palatability and bidirectionally regulate hedonic food consumption. Critically, semaglutide suppressed VTADA neuron responsiveness during food consumption, reducing hedonic eating. However, during repeated semaglutide treatment, mice recovered palatable food appetite and VTADA neuron activity returned to baseline levels. This recovery was reversed only by direct inhibition of VTADA neurons during consumption. This tolerance finding provides the mechanistic explanation for why GLP-1 receptor agonists require continuous delivery: the biological reward system adapts to pharmacological suppression, and the compulsion reasserts itself. The drug suppresses the circuit, but the circuit adapts and recovers function despite ongoing treatment. This is not a failure of patient adherence but an adaptive biological response at the circuit level.

inbox/archive/health/2026-04-23-science-hedonic-eating-dopamine-glp1.md

@@ -7,9 +7,12 @@ date: 2025-03-01
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-23
 priority: high
 tags: [glp-1, dopamine, VTA, hedonic-eating, reward-circuitry, neuroscience, obesity, behavioral-dichotomy, semaglutide]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content